

Ondrej Fiala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4357346/publications.pdf>

Version: 2024-02-01

57
papers

764
citations

623734

14
h-index

642732

23
g-index

59
all docs

59
docs citations

59
times ranked

1650
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Tumor Cell Kinetics and Morphology from the Liquid Biopsy Predict Disease Progression in Patients with Metastatic Colorectal Cancer Following Resection. <i>Cancers</i> , 2022, 14, 642.	3.7	3
2	Combination of Circulating Tumour DNA and ¹⁸ F-FDG PET/CT for Precision Monitoring of Therapy Response in Patients With Advanced Non-small Cell Lung Cancer: A Prospective Study. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 270-281.	2.0	4
3	Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis. <i>Cancers</i> , 2022, 14, 1410.	3.7	0
4	A large-scale assay library for targeted protein quantification in renal cell carcinoma tissues. <i>Proteomics</i> , 2022, 22, 2100228.	2.2	0
5	Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib. <i>Cancer Management and Research</i> , 2021, Volume 13, 4077-4086.	1.9	7
6	Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line. <i>Targeted Oncology</i> , 2021, 16, 643-652.	3.6	7
7	Octreotide in the treatment of malignant thymoma – Case report. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 882-885.	0.6	3
8	Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy – Data from the National Renis Registry. <i>Cancers</i> , 2020, 12, 2911.	3.7	9
9	Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 605-613.	2.0	6
10	Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients. <i>Cancer Management and Research</i> , 2020, Volume 12, 5365-5372.	1.9	8
11	Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors. <i>Anticancer Research</i> , 2020, 40, 1219-1227.	1.1	26
12	Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients. <i>Cancers</i> , 2020, 12, 808.	3.7	10
13	Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. <i>Targeted Oncology</i> , 2020, 15, 193-201.	3.6	4
14	Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib. <i>Oncology Letters</i> , 2020, 20, 1376-1382.	1.8	3
15	Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis. <i>Cancer Management and Research</i> , 2019, Volume 11, 359-368.	1.9	8
16	The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents. <i>Anticancer Research</i> , 2019, 39, 5645-5652.	1.1	9
17	MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 353-359.	2.0	17
18	Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 294.e1-294.e8.	1.6	4

#	ARTICLE	IF	CITATIONS
19	Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients. <i>Cancers</i> , 2019, 11, 1856.	3.7	15
20	The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line. <i>Journal of Cancer</i> , 2018, 9, 4255-4262.	2.5	2
21	An Assessment of Novel Biomarkers in Bone Metastatic Disease Using Multiplex Measurement and Multivariate Analysis. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381880746.	1.9	2
22	Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis. <i>Targeted Oncology</i> , 2018, 13, 735-743.	3.6	6
23	CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer. <i>Anticancer Research</i> , 2018, 38, 465-469.	1.1	9
24	Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response. <i>Anticancer Research</i> , 2018, 38, 2961-2965.	1.1	11
25	Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. <i>Tumor Biology</i> , 2017, 39, 101042831769118.	1.8	12
26	The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab. <i>Tumor Biology</i> , 2017, 39, 101042831770928.	1.8	24
27	Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1047-e1053.	1.9	7
28	Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. <i>BMC Cancer</i> , 2017, 17, 880.	2.6	10
29	MIC1/GDF15 as a Bone Metastatic Disease Biomarker. <i>Anticancer Research</i> , 2017, 37, 1501-1506.	1.1	22
30	Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC. <i>Anticancer Research</i> , 2017, 37, 6469-6476.	1.1	11
31	Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. <i>Drugs and Aging</i> , 2016, 33, 655-663.	2.7	15
32	Comparison of transcranial sonography-magnetic resonance fusion imaging in Wilson's and early-onset Parkinson's diseases. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 87-93.	2.2	16
33	G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. <i>Tumor Biology</i> , 2016, 37, 6823-6830.	1.8	38
34	Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis. <i>European Urology</i> , 2016, 70, 469-475.	1.9	41
35	Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene. <i>Anticancer Research</i> , 2016, 36, 447-53.	1.1	2
36	Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC. <i>Anticancer Research</i> , 2016, 36, 455-60.	1.1	9

#	ARTICLE	IF	CITATIONS
37	Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy. <i>Anticancer Research</i> , 2016, 36, 461-6.	1.1	6
38	The Role of TPS and TPA in the Diagnostics of Distant Metastases. <i>Anticancer Research</i> , 2016, 36, 773-7.	1.1	9
39	The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy. <i>Anticancer Research</i> , 2016, 36, 1077-82.	1.1	18
40	Searching for New Biomarkers and the Use of Multivariate Analysis in Gastric Cancer Diagnostics. <i>Anticancer Research</i> , 2016, 36, 1967-71.	1.1	7
41	Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study. <i>Anticancer Research</i> , 2016, 36, 1973-8.	1.1	13
42	Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib. <i>Anticancer Research</i> , 2016, 36, 2459-65.	1.1	13
43	EEG correlates of a mental arithmetic task in patients with first episode schizophrenia and schizoaffective disorder. <i>Clinical Neurophysiology</i> , 2015, 126, 2090-2098.	1.5	33
44	Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation. <i>Tumor Biology</i> , 2015, 36, 5801-5805.	1.8	29
45	High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib. <i>Tumor Biology</i> , 2015, 36, 9215-9222.	1.8	17
46	Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency. <i>European Journal of Cancer</i> , 2015, 51, 507-513.	2.8	12
47	The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study. <i>Targeted Oncology</i> , 2015, 10, 549-555.	3.6	5
48	Eye Movements in Ephedrone-Induced Parkinsonism. <i>PLoS ONE</i> , 2014, 9, e104784.	2.5	15
49	Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis. T.B. and B.M. received honoraria for advisory boards and lectures from Novartis and Pfizer. K.K. received honoraria for advisory boards and lectures from Novartis. Other authors have declared no conflict of interest. The RENIS registry is funded in part by pharmaceutical companies producing targeted agents for renal cancer (Pfizer, Bayer, GSK, Roche, and Novartis). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 569-575.	1.6	12
50	Parkin (PARK 2) Mutations Are Rare in Czech Patients with Early-Onset Parkinson's Disease. <i>PLoS ONE</i> , 2014, 9, e107585.	2.5	14
51	Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib. <i>Anticancer Research</i> , 2014, 34, 3205-10.	1.1	26
52	The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy of EGFR-TKIs in patients with advanced-stage NSCLC [corrected]. <i>Anticancer Research</i> , 2014, 34, 5193-8.	1.1	12
53	Predictive and prognostic significance of sodium levels in patients with NSCLC treated by erlotinib. <i>Anticancer Research</i> , 2014, 34, 7461-5.	1.1	14
54	The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <i>Cancer Genetics</i> , 2013, 206, 26-31.	0.4	56

#	ARTICLE	IF	CITATIONS
55	Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy. <i>Anticancer Research</i> , 2013, 33, 1705-11.	1.1	24
56	Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence. <i>Anticancer Research</i> , 2013, 33, 3397-402.	1.1	7
57	Parkin mutations and phenotypic features in Czech patients with early-onset Parkinson's disease. <i>Neuroendocrinology Letters</i> , 2010, 31, 187-92.	0.2	6